NM107 (Synonyms: 2'-C-甲基胞嘧啶核苷; 2'-C-Methylcytidine)

目录号: HY-10468 纯度: 99.23%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

NM107 (2'-C-Methylcytidine) 是丙型肝炎病毒 (HCV) NS5B 聚合酶的核苷抑制剂，其在野生型复制子细胞中的 EC₅₀ 为 1.85 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NM107 Chemical Structure

CAS No. : 20724-73-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
Free Sample (0.1 - 0.2 mg)		Apply now
10 mM * 1 mL in DMSO	￥660	In-stock
5 mg	￥600	In-stock
10 mg	￥900	In-stock
50 mg	￥1600	In-stock
100 mg	￥2600	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

NM107 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC₅₀ of NM107 in the wild-type replicon cells is 1.85 μM^[1]^[2].

IC₅₀ & Target

HCV^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
BHK-21	EC₅₀	> 100 μM Compound: Met-Cyt	Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay	[PMID: 26479028]
BHK-21	EC₅₀	> 100 μM Compound: Met-Cyt	Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	[PMID: 25014745]
BHK-21	CC₅₀	> 100 μM Compound: 2'-MeCyt	Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 22047799]
BHK-21	CC₅₀	> 100 μM Compound: 2'-MeCyt	Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27161176]
BHK-21	CC₅₀	> 100 μM Compound: NM 107	Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method	[PMID: 25913116]
BHK-21	CC₅₀	> 100 μM Compound: 2'-C-methyl-cytidine	Cytotoxicity against BHK21 cells by MTT assay Cytotoxicity against BHK21 cells by MTT assay	[PMID: 22513121]
BHK-21	EC₅₀	16 μM Compound: 2'-MeCyt	Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 27161176]
BHK-21	EC₅₀	16 μM Compound: Met-Cyt	Antiviral activity against Simian virus 12 3651 (ATCC VR- 214) infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method Antiviral activity against Simian virus 12 3651 (ATCC VR- 214) infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	[PMID: 25014745]
BHK-21	EC₅₀	16 μM Compound: 2'-C-methyl-cytidine	Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 22513121]
BHK-21	EC₅₀	16 μM Compound: 2'-MeCyt	Antiviral activity against Reovirus type-1 3651 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 3651 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 22047799]
BHK-21	EC₅₀	6 μM Compound: NM 107	Antiviral activity against Reovirus 1 infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method Antiviral activity against Reovirus 1 infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method	[PMID: 25913116]
CCRF-CEM	CC₅₀	> 100 μM Compound: 2'C-MeC	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay	[PMID: 28595015]
CCRF-CEM	CC₅₀	22 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay	[PMID: 30653317]
CCRF-CEM	IC₅₀	54.4 μM Compound: NM-107	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method	[PMID: 22014549]
Huh-5-2	CC₅₀	> 33 μM Compound: 2'-C-Methylcytidine	Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay	[PMID: 18625766]
Huh-5-2	EC₅₀	2 μM Compound: 2'-C-Methylcytidine	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay	[PMID: 18625766]
Huh-7	CC₅₀	> 10 μM Compound: 2'C-MeC	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay	[PMID: 28595015]
Huh-7	CC₅₀	> 10 μM Compound: NM-107	Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs	[PMID: 22014549]
Huh-7	CC₅₀	> 100 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay	[PMID: 30653317]
Huh-7	CC₅₀	> 100 μM Compound: 2'-C-MeCyd	Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay	[PMID: 16107149]
Huh-7	CC₅₀	> 300 μM Compound: 2'-C-Me-C, NM107	Cytotoxicity against human HuH7 cells expressing E2 glycoprotein assessed as reduction of rRNA level after 5 days Cytotoxicity against human HuH7 cells expressing E2 glycoprotein assessed as reduction of rRNA level after 5 days	[PMID: 21621997]
Huh-7	CC₅₀	> 33 μM Compound: 2'-C-Me-C	Cytotoxicity against human HuH7 cells after 72 hrs Cytotoxicity against human HuH7 cells after 72 hrs	[PMID: 21880398]
Huh-7	CC₅₀	> 50 μM Compound: 2'-C-Me-C	Cytotoxicity against human Huh7 cells assessed as rRNA level after 5 days Cytotoxicity against human Huh7 cells assessed as rRNA level after 5 days	[PMID: 19072694]
Huh-7	CC₅₀	> 89 μM Compound: 2'-C-Me C	Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay	[PMID: 22578461]
Huh-7	CC₅₀	> 98 μM Compound: 8a, NM-107	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 3 days by BrdU incorporation assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 3 days by BrdU incorporation assay	[PMID: 24345201]
Huh-7	CC₅₀	> 98.4 μM Compound: 1, NM-107	Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay	[PMID: 21033671]
Huh-7	EC₅₀	0.23 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.48 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.62 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1 μM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1.1 μM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1.23 μM Compound: NM-107	Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay	[PMID: 18285474]
Huh-7	EC₅₀	1.3 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1.7 μM Compound: 2'-C-Me-C, NM107	Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days	[PMID: 21621997]
Huh-7	EC₅₀	11.2 μM Compound: 2CMC	Antiviral activity against Dengue virus 2 DN454009A infected in human HuH7 cells assessed as inhibition of viral RNA level measured 72 hrs post infection by qRT-PCR method Antiviral activity against Dengue virus 2 DN454009A infected in human HuH7 cells assessed as inhibition of viral RNA level measured 72 hrs post infection by qRT-PCR method	[PMID: 26988299]
Huh-7	EC₅₀	1143 nM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	1623 nM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	2.4 μM Compound: 2'-C-Me-C	Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 21880398]
Huh-7	EC₅₀	2.5 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	2.5 μM Compound: 19	Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay	[PMID: 25650256]
Huh-7	EC₅₀	2.8 μM Compound: NM-107	Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR	[PMID: 22014549]
Huh-7	EC₅₀	2.8 μM Compound: 19	Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay	[PMID: 25650256]
Huh-7	EC₅₀	3.5 μM Compound: 2'-C-Me-C	Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay	[PMID: 19072694]
Huh-7	EC₅₀	4.07 μM Compound: 2'-C-Me C	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs	[PMID: 22578461]
Huh-7	EC₅₀	4.6 μM Compound: 8a, NM-107	Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay	[PMID: 24345201]
Huh-7	EC₅₀	4.6 μM Compound: 1, NM-107	Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay	[PMID: 21033671]
Huh-7	CC₅₀	94.75 μM Compound: 2CMC	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 26988299]
MT4	CC₅₀	> 98.4 μM Compound: 1, NM-107	Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay	[PMID: 21033671]
PBMC	CC₅₀	> 100 μM Compound: 2'C-MeC	Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay	[PMID: 28595015]
PBMC	IC₅₀	47.4 μM Compound: NM-107	Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method	[PMID: 22014549]
PBMC	CC₅₀	60 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay	[PMID: 30653317]
Vero	CC₅₀	> 100 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay	[PMID: 30653317]
Vero	CC₅₀	> 100 μM Compound: 2'C-MeC	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay	[PMID: 28595015]
Vero	IC₅₀	> 100 μM Compound: NM-107	Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis	[PMID: 22014549]
Vero	EC₅₀	18 μM Compound: 2'-C-methyl-cytidine	Antiviral activity against Human coxsackievirus B5 ATCC VR-29 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining Antiviral activity against Human coxsackievirus B5 ATCC VR-29 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	7.3 μM Compound: 2'-C-methyl-cytidine	Antiviral activity against Poliovirus type 1 ATCC VR-1562 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 2 days by crystal violet staining Antiviral activity against Poliovirus type 1 ATCC VR-1562 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 2 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	94 μM Compound: 2'-CMC	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay	[PMID: 22310228]
Vero 76	CC₅₀	> 100 μM Compound: 2'-C-methyl-cytidine	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	16 μM Compound: Met-Cyt	Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 26479028]

体外研究
(In Vitro)

NM107 (25 μM；24 小时；Huh7-1 细胞和细胞培养繁殖的 HCV) 处理可降低细胞外病毒滴度和细胞内 RNA 水平。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[2]

Cell Line:	Huh7-1 cells and cell culture-propagated HCV (HCVcc)
Concentration:	25 μM
Incubation Time:	24 hours
Result:	Extracellular virus titers declined in parallel with intracellular RNA levels.

分子量

257.24

Formula

C₁₀H₁₅N₃O₅

CAS 号

20724-73-6

性状

固体

颜色

White to off-white

中文名称

2'-C-甲基胞嘧啶核苷

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (388.74 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : ≥ 50 mg/mL (194.37 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.8874 mL	19.4371 mL	38.8742 mL
5 mM	0.7775 mL	3.8874 mL	7.7748 mL
10 mM	0.3887 mL	1.9437 mL	3.8874 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.72 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.72 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.72 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 50 mg/mL (194.37 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.23%

选择批次：

Data Sheet (628 KB) SDS (393 KB)

COA (289 KB) LCMS (95 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Mathy JE, et al, Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother. 2008 Sep;52(9):3267-75. [Content Brief]

[2]. Guedj J, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. [Content Brief]

NM107 相关分类

Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	3.8874 mL	19.4371 mL	38.8742 mL	97.1855 mL
	5 mM	0.7775 mL	3.8874 mL	7.7748 mL	19.4371 mL
	10 mM	0.3887 mL	1.9437 mL	3.8874 mL	9.7186 mL
	15 mM	0.2592 mL	1.2958 mL	2.5916 mL	6.4790 mL
	20 mM	0.1944 mL	0.9719 mL	1.9437 mL	4.8593 mL
	25 mM	0.1555 mL	0.7775 mL	1.5550 mL	3.8874 mL
	30 mM	0.1296 mL	0.6479 mL	1.2958 mL	3.2395 mL
	40 mM	0.0972 mL	0.4859 mL	0.9719 mL	2.4296 mL
	50 mM	0.0777 mL	0.3887 mL	0.7775 mL	1.9437 mL
	60 mM	0.0648 mL	0.3240 mL	0.6479 mL	1.6198 mL
	80 mM	0.0486 mL	0.2430 mL	0.4859 mL	1.2148 mL
	100 mM	0.0389 mL	0.1944 mL	0.3887 mL	0.9719 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NM10720724-73-62'-C-Methylcytidine2'-C-甲基胞嘧啶核苷NM 107NM-107HCVHepatitis C virusInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

NM107 (Synonyms: 2'-C-甲基胞嘧啶核苷; 2'-C-Methylcytidine)

Customer Review

NM107 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

NM107 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

NM107 (Synonyms: 2'-C-甲基胞嘧啶核苷; 2'-C-Methylcytidine)

Customer Review

NM107 相关抗体

NM107 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

NM107 相关抗体:

摩尔计算器

稀释计算器

NM107 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z